READ | Jotup

Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc.

Retrieved on:

星期二, 十月 24, 2023

CRANFORD, N.J. and NEW YORK, N.Y., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Citius Pharmaceuticals, Inc. (“Citius Pharma” or the “Company”) (Nasdaq: CTXR), a biopharmaceutical company developing and commercializing first-in-class critical care products, and TenX Keane Acquisition (“TenX”) (NASDAQ: TENKU), a publicly traded special purpose acquisition company (SPAC), today announced that they have entered into a definitive agreement, dated October 23, 2023, for a proposed merger of TenX and Citius Pharma’s wholly owned oncology subsidiary that will continue as a public company listed on the Nasdaq exchange. The newly combined public company will be named Citius Oncology, Inc. (“Citius Oncology”). Upon closing, pursuant to the terms of the merger agreement, Citius Pharma would receive 67.5 million shares in Citius Oncology at $10 per share and retain majority ownership of approximately 90%. The transaction has been approved by the Board of Directors of both companies and is expected to close in the first half of 2024.

Key Points:

The newly combined public company will be named Citius Oncology, Inc. (“Citius Oncology”).
Our majority ownership position and shared services agreement ensures that the Citius Pharma management team will remain fully engaged with the development and commercialization efforts at Citius Oncology.
“We are very pleased to announce the proposed merger with Citius Oncology,” said Mr. Xiaofeng Yuan, Chairman and CEO of TenX.
In the transaction, all shares of Citius Pharma’s wholly owned subsidiary would be converted into the right to receive common stock of Citius Oncology.

Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc.

Retrieved on:

星期二, 十月 24, 2023

CRANFORD, N.J. and NEW YORK, Oct. 24, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company developing and commercializing first-in-class critical care products, and TenX Keane Acquisition ("TenX") (NASDAQ: TENKU), a publicly traded special purpose acquisition company (SPAC), today announced that they have entered into a definitive agreement, dated October 23, 2023, for a proposed merger of TenX and Citius Pharma's wholly owned oncology subsidiary that will continue as a public company listed on the Nasdaq exchange. The newly combined public company will be named Citius Oncology, Inc. ("Citius Oncology"). Upon closing, pursuant to the terms of the merger agreement, Citius Pharma would receive 67.5 million shares in Citius Oncology at $10 per share and retain majority ownership of approximately 90%. The transaction has been approved by the Board of Directors of both companies and is expected to close in the first half of 2024.

Key Points:

The newly combined public company will be named Citius Oncology, Inc. ("Citius Oncology").
"We are very pleased to announce the proposed merger with Citius Oncology," said Mr. Xiaofeng Yuan, Chairman and CEO of TenX.
Pursuant to the proposed agreement, TenX will acquire Citius Pharma's wholly owned subsidiary via a merger, with the newly combined publicly traded company to be named Citius Oncology, Inc.
In the transaction, all shares of Citius Pharma's wholly owned subsidiary would be converted into the right to receive common stock of Citius Oncology.

Scott+Scott Attorneys At Law LLP and Berger Montague PC Announce Notice of Pendency and Proposed Settlement For All Persons And Entities Who Purchased or Otherwise Acquired The Publicly Traded American Depositary Shares of Cloopen Group Holding Limited, D

Retrieved on:

星期一, 十月 23, 2023

(the "Federal Action"), have reached a proposed settlement of both Actions for $12,000,000 in cash on behalf of the Settlement Class, that, if approved, will resolve all claims in both Actions.

Key Points:

(the "Federal Action"), have reached a proposed settlement of both Actions for $12,000,000 in cash on behalf of the Settlement Class, that, if approved, will resolve all claims in both Actions.
Please do not contact the Court, the Clerk's office, Cloopen, the other Defendants, or their counsel regarding this notice.
All questions about this notice, the proposed Settlement, or your eligibility to participate in the Settlement should be directed to Class Counsel or the Claims Administrator.
Inquiries may be made to the Claims Administrator at www.CloopenSecuritiesLitigation.com , or to Settlement Class Counsel:

READING IS FUNDAMENTAL LAUNCHES THIRD ANNUAL NATIONWIDE READING ENGAGEMENT INITIATIVE "RALLY TO READ 100"

Retrieved on:

星期一, 十月 2, 2023

WASHINGTON, Oct. 2, 2023 /PRNewswire/ -- Reading Is Fundamental (RIF), the nation's leading children's literacy nonprofit, announced today the launch of the third annual Rally to Read 100 (RallytoRead.org)—a six-month initiative that runs from October 1, 2023 to March 31, 2024 that is designed to inspire the joy of reading and motivate children to read, starting with a pledge to read 100 books.

Key Points:

Celebrate reading for six months straight with sweepstakes, monthly themes, reading activities, and read-alouds from bestselling authors.
"Barnes & Noble is excited to once again partner with Reading Is Fundamental and unite forces for this year's Rally to Read 100 campaign," said Jackie De Leo, Chief Merchandising Officer, Barnes & Noble.
We cannot wait to see the impact of this year's initiative in classrooms across the country and young readers nationwide."
RALLY TO READ 100 PROGRAM ELEMENTS:
Pledge to Read 100 Books: Participants can pledge to read 100 books over six months and receive engaging content and book recommendations to support this goal.

QuidelOrtho Receives CLIA Waiver for Sofia® 2 SARS Antigen+ FIA

Retrieved on:

星期四, 九月 21, 2023

QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it has been granted CLIA Waiver from the U.S. Food and Drug Administration (FDA), applying to its new Sofia® 2 SARS Antigen+ FIA.

Key Points:

QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it has been granted CLIA Waiver from the U.S. Food and Drug Administration (FDA), applying to its new Sofia® 2 SARS Antigen+ FIA.
The Sofia 2 SARS Antigen+ FIA is the first rapid antigen test that detects COVID-19 to be awarded FDA market clearance through the FDA’s De Novo process and is now the first rapid antigen test also to receive CLIA waiver.
With the CLIA waiver, the Sofia 2 SARS Antigen+ FIA is deemed to be so simple and at such low risk of error that it no longer requires administration by trained clinical laboratory personnel, opening broader use in virtually any point-of-care setting equipped with Sofia 2 instruments.
“As the first company to introduce a rapid antigen test for COVID-19 when the FDA granted Emergency Use Authorization for the Sofia SARS Antigen FIA in May of 2020, and the first to receive De Novo FDA clearance for our Sofia 2 SARS Antigen+ FIA, it is gratifying to also be the first to receive a full CLIA waiver for our Sofia 2 SARS Antigen+ FIA,” said Douglas Bryant, President and Chief Executive Officer of QuidelOrtho.

Legible To Launch 'Unbound' Membership Service and AI-Powered Mobile App on September 29, 2023

Retrieved on:

星期四, 九月 14, 2023

View the full release here: https://www.businesswire.com/news/home/20230914394779/en/

Key Points:

View the full release here: https://www.businesswire.com/news/home/20230914394779/en/
Legible Unbound Membership Plan: At a competitive monthly fee of $12.99, Legible Unbound represents a strategic entry into the subscription-based digital content market.
AI & Multimedia Content: Legible’s Unbound membership service will include access to brand-new digital reading entertainment products featuring enriched multimedia content and interactive AI within groundbreaking new eBooks published exclusively by Legible.
The Legible Mobile App: Legible will also be launching the Company’s Mobile App designed to cater to reader needs and preferences and complement its new Unbound membership service.
"With the imminent launch of Legible Unbound and our new Mobile App, we have set a path to generate monthly recuring revenue, along with revenues from a-la-carte eBook and audiobook sales,” stated Kaleeg Hainsworth, CEO of Legible.

Legible Secures Worldwide Rights to Stan Lee's Workforce in Landmark Deal With Kartoon Studios

Retrieved on:

星期五, 九月 8, 2023

Jon Ollwerther, Executive Vice President of Business Development at Kartoon Studios, commented, “Legible is a consummate partner to Kartoon Studios and as the publisher of Stan Lee Comics Legible already has deep knowledge of Stan Lee and his catalogue.

Key Points:

Jon Ollwerther, Executive Vice President of Business Development at Kartoon Studios, commented, “Legible is a consummate partner to Kartoon Studios and as the publisher of Stan Lee Comics Legible already has deep knowledge of Stan Lee and his catalogue.
They were the obvious choice to bring Stan Lee’s Workforce to readers around the world.”
The news follows the recent announcement that Stan Lee Universe (a joint venture between Kartoon Studios and POW!)
selected Legible as a leading online eBook streaming platform and multimedia publisher to develop and distribute approximately 12 original comic book series based on never-before-seen Stan Lee creations.
“Legible is the perfect partner for this creative digital innovation and will bring so much entertainment to existing and new Stan Lee fans worldwide,” said Michael Uslan.

Industry Titan Vyomesh Joshi, Retired Hewlett Packard EVP, Joins Legible as Strategic Advisor

Retrieved on:

星期三, 九月 6, 2023

"We are excited to welcome Vyomesh Joshi as a Strategic Advisor," said Kaleeg Hainsworth, CEO of Legible.

Key Points:

"We are excited to welcome Vyomesh Joshi as a Strategic Advisor," said Kaleeg Hainsworth, CEO of Legible.
In his role as a Strategic Advisor, Mr. Joshi will collaborate closely with Legible's executive team providing strategic insights, guidance on market positioning, and opportunities for product innovation.
"I am honoured to join the Legible team as a Strategic Advisor," Vyomesh Joshi commented.
This strategic collaboration comes at a time when Legible is preparing to launch numerous revenue streams in its expanding role as a leading digital entertainment disruptor and innovator.

Glancy Prongay & Murray LLP Announces Pendency of Class Action and Proposed Settlement Involving Purchasers of Eros Shares and/or Common Stock

Retrieved on:

星期一, 八月 21, 2023

YOU ARE ALSO NOTIFIED that Lead Plaintiffs in the Action have reached a proposed settlement of the Action for $25,000,000 in cash (the "Settlement"), that, if approved, will resolve all claims in the Action.

Key Points:

YOU ARE ALSO NOTIFIED that Lead Plaintiffs in the Action have reached a proposed settlement of the Action for $25,000,000 in cash (the "Settlement"), that, if approved, will resolve all claims in the Action.
If you are a member of the Settlement Class, your rights will be affected by the pending Action and the Settlement, and you may be entitled to share in the Settlement Fund.
If you are a member of the Settlement Class, in order to be eligible to receive a payment under the proposed Settlement, you must submit a Claim Form postmarked no later than December 6, 2023.
All questions about this notice, the proposed Settlement, or your eligibility to participate in the Settlement should be directed to Lead Counsel or the Claims Administrator.

Kartoon Studios Provides Business Update for the Second Quarter of 2023

Retrieved on:

星期一, 八月 14, 2023

BEVERLY HILLS, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Kartoon Studios (NYSE American:TOON) today provided a business update for the second quarter of 2023.

Key Points:

BEVERLY HILLS, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Kartoon Studios (NYSE American:TOON) today provided a business update for the second quarter of 2023.
Although the strike is ongoing, neither Kartoon Studios nor its subsidiaries are signatories of WGA or SAG.
As a result, Kartoon Studios is now less dependent on third-party networks for distributing our content.
As of June 30, 2023, Kartoon Studios had current assets of $91.6 million, working capital of $14.4 million, and total stockholders’ equity of $87.5 million.